ACR Convergence 2025

Nanoencapsulated sirolimus plus pegadricase reduced disease burden in patients with uncontrolled gout, phase 3 study data show

Presenters: Puja Khanna, MD, MPH, Division of Rheumatology, University of Michigan, Ann Arbor, MI; Angelo Gaffo, MD, Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL

Nanoencapsulated sirolimus plus pegadricase reduced disease burden in patients with uncontrolled gout: results from the phase 3 DISSOLVE trials. Abstract 2587. Presented October 28, 2025.

Nanoencapsulated sirolimus plus pegadricase (NASP) demonstrates a reduction in gout flares: results from the phase 3 DISSOLVE studies. Abstract 2588. Presented October 28, 2025.

Ianalumab significantly improved disease activity and symptoms in patients Sjögren’s disease, phase 3 trials show

Presenter: Thomas Grader-Beck, MD, Johns Hopkins Sjögren’s Center, Baltimore, MD.

Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: efficacy and safety results from two global phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2). Abstract LB24. Presented October 29, 2025.

Novel pathogenic T cell-targeting monoclonal antibody yields durable responses in rheumatoid arthritis, study shows

Presenter: Paul Emery, MD, FRCP, MA, MBBCH, University of Leeds, Leeds, United Kingdom.

Rosnilimab, a selective and potent depleter of pathogenic T cells, demonstrates efficacy, safety, and translational proof of mechanism in a rheumatoid arthritis phase 2B trial. Abstract LB19. Presented October 29, 2025.

Bispecific CAR T-cell therapy yields durable responses in treatment-refractory autoimmune diseases, study shows

Presenter: Nan Shen, MD, PhD, Director, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China

Anti-CD20/BCMA bispecific CAR-T cell therapy promotes immune reset and sustained drug free remission in refractory autoimmune diseases. Abstract LB04. Presented October 28, 2025.

Deucravacitinib has favorable safety, sustained efficacy through 52 weeks in adults with active psoriatic arthritis, phase 3 data show

Presenter: Philip J. Mease, MD, Director, Rheumatology Research, Providence Swedish Medical Center and Clinical Professor, University of Washington, Seattle

Efficacy and safety of deucravacitinib up to week 52: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drugs. Abstract LB20. Presented October 29, 2025.

Rheumatologists, nephrologists split on best care pathway for uncontrolled gout, survey suggests

Presenter: Shilpa Sharan, PhD, The HWP Group, Upper Saddle River, NJ

Survey of healthcare providers’ knowledge and attitudes toward the management of uncontrolled gout. Abstract 2192. Presented October 28, 2025.

Novel gout therapies demonstrate early promise in recent studies

Presenters: Robert T. Keenan, MD, MPH; Ullrich Schwertschlag, MD, PhD; Yu Xue, MD, PhD

Efficacy of pozdeutinurad (AR882) in treatment naïve and suboptimally treated gouty arthritis with tophi. Abstract 1138. Presented October 27, 2025.

Real-world survey data reveal persistent gaps in management of uncontrolled gout

Presenter: John A. Albert, MD, Physician/Partner, Rheumatic Disease Center, Glendale, WI

The care pathway and treatment patterns in patients with uncontrolled gout: a real-world survey of physicians in the United States. Abstract 1043. Presented Oct 27, 2025

Nanoencapsulated sirolimus plus pegadricase well tolerated with sustained efficacy over time in patients with uncontrolled gout, post hoc analysis finds

Presenter: Alan Kivitz, MD, Altoona Center for Clinical Research, Duncansville, PA

Nanoencapsulated sirolimus plus pegadricase (NASP) demonstrates long term efficacy and safety in patients with uncontrolled gout: results from the 24-week double-blind extension of the phase 3 DISSOLVE I Study. Abstract 1123. Presented October 27, 2025.